Study of Osteogenesis Imperfecta Tendon
Launched by UNIVERSITÉ CATHOLIQUE DE LOUVAIN · Sep 26, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called osteogenesis imperfecta (OI), which is a rare genetic disorder that causes fragile bones and can lead to fractures and deformities. Researchers want to learn more about how OI affects tendons and ligaments, as these are important for movement and overall quality of life. Previous reports have mentioned tendon ruptures in patients with OI, but this is the first study to closely examine the issue.
If you or a family member have osteogenesis imperfecta, you may be eligible to participate in this trial. There are no specific age limits or exclusions, so people of all ages with OI can join. Participants will be asked to share their experiences and may undergo various assessments to help researchers understand the impact of OI on tendons and ligaments. This study aims to provide valuable insights that could improve care and management for those living with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • to have an osteogenesis imperfecta
- Exclusion Criteria:
- • none, since we want to study different types of osteogenesis imperfecta and consider the effect of age.
About Université Catholique De Louvain
Université Catholique de Louvain (UCLouvain) is a prestigious Belgian institution renowned for its commitment to academic excellence, research innovation, and interdisciplinary collaboration. With a strong emphasis on advancing medical science and improving patient outcomes, UCLouvain conducts a range of clinical trials across various medical fields. The university's research initiatives are supported by cutting-edge facilities and a team of experienced professionals, fostering a robust environment for clinical investigation. UCLouvain is dedicated to ethical research practices and aims to contribute significantly to the global body of medical knowledge through its clinical trial endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Woluwe Saint Lambert, Brussels, Belgium
Patients applied
Trial Officials
Pierre-Louis Docquier, MD
Principal Investigator
Cliniques Univresitaires Saint-Luc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported